Purohit’s continued optimism is primarily driven by the strong commercial performance of Auvelity, the company’s treatment ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS ...

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Across the recent three months, 16 analysts have shared their insights on Axsome Therapeutics AXSM, expressing a variety of opinions spanning from bullish to bearish. In the table below ...

Axsome Therapeutics, Inc. has announced a settlement with Hetero Labs Ltd. regarding patent litigation over its product SUNOSI® (solriamfetol). The litigation arose from Hetero's application to ...

Axsome Therapeutics and Hetero Labs agreed to settle to resolve patent litigation claims. The litigation, which is pending in a New Jersey district court, resulted from Hetero submitting an ...

Many investors love the "big mo." That's short for "big momentum." Stocks that are on a roll often keep the good times going.